Determination of rizatriptan in human plasma by liquid chromatographic-eletrospray tandem mass spectrometry: Application to a pharmacokinetic study

Biomedical Chromatography

Volumn 20, Issue 1, 2006, Pages 61-66

  Guo, Ji Fen ^a   Zhang, Ai Jun ^a   Zhao, Ling ^a   Sun, Xiao Hong ^a   Zhao, Yi Min ^a   Gao, Hong Zhi ^b   Liu, Ze Yuan ^b   Qiao, Shan Yi ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Beijing 307 Hospital   (China)

Author keywords

LC MS MS; Pharmacokinetics; Rizatriptan

Indexed keywords

ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN); QUALITY CONTROL;

ANALYTES; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; LIQUID-LIQUID EXTRACTION; PHARMACOKINETIC STUDIES; PLASMA SAMPLES; RIZATRIPTAN; TANDEM MASS SPECTROMETRY; TANDEM-MASS SPECTROMETRY;

PHARMACOKINETICS;

RIZATRIPTAN; ZOLMITRIPTAN;

ACCURACY; ADULT; ANALYZER; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PROCESS DEVELOPMENT; QUALITY CONTROL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

EID: 31344457418     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.528     Document Type: Article

References (7)

1. Chen J, Jiang XG, Jiang WM, Ni Mei, Gao XL and Zhang QZ. Liquid chromatographic method for the determination of rizatriptan in human plasma. Journal of Chromatography B 2004; 805: 169-173.
2. Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, Mcloughlin DA, Olah TV, De Smet M, Keymeulen B and Rogers JD. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. British Journal of Clinical Pharmacology 1999; 47: 373-378.
3. McLoughlin DA, Olah TV, Ellis JD, Gilbert JD and Halpin RA. Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Chromatography B 1996; 726: 115-124.
4. Sciberras DG., Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M and Mant T. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. British Journal of Clinical Pharmacology 1997; 43: 49-54.
5. Vishwanathan K, Bartlett MG and Stewart JT. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2000; 14: 168-172.
6. Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez Eng C, Matuszewski BK, Varga SL, Guiblin AR and Rogers JD. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metabolism and Disposition 2000; 28: 89-95.
7. Wellington K and Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs 2002; 62: 1539-1574.